Signal activated RNA interference
The invention provides compositions and methods for signal activated RNA interference (saRNAi), preferably in vivo. The invention provides polynucleotides that switches between an inactive form and an active form upon covalent or non-covalent interaction with one or more specific chemical signals, such as disease-specific mRNA, miRNA, or other cellular RNA products with sequences that characterize diseased states of the cell. The interaction between the subject polynucleotides and the signals is preferably mediated by hybridization, which exposes, facilitates the formation, and/or allows the formation of a substrate that can be processed by proteins of the RNAi pathway (such as Dicer). The input and output of multiple different polynucleotides of the invention can form an in vivo signaling network. In addition, the multiple input signals can be integrated to modulate the activity of the subject polynucleotides.
1. A signal-activatable polynucleotide construct for enzyme-assisted molecular delivery, the construct comprising:
a targeting domain and
a sensor domain covalently bound to the targeting domain, the sensor domain comprising:
a signal detection region complementary to at least one signal polynucleotide,
a first chimeric sequence comprising at least one RNA region,
a second chimeric sequence comprising a DNA region complementary to an RNA region of the at least one RNA regions of the first chimeric sequence, and
a masking segment complementary to the first chimeric sequence;
wherein the sensor domain is configured such that:
in absence of the signal polynucleotide,
the masking segment hybridizes with the first chimeric sequence,
the DNA region of the second chimeric sequence is in a configuration not processable by RNase H, and
the signal detection region is presented for binding to the signal polynucleotide; and
in presence of the signal polynucleotide,
the signal detecting region hybridizes with the signal polynucleotide,
the masking segment is displaced from the first chimeric sequence, and
the DNA region of the second chimeric sequence hybridizes with the complementary RNA region of the at least RNA region of the first chimeric sequence to provide an RNase H binding site presented for binding to RNase H, and
the sensor domain is configured to allow release of the targeting domain from the sensor domain upon cleavage of the RNase H binding site by the RNase H.
2. The signal activatable construct of claim 1 , wherein the second chimeric sequence and the targeting domain are located at opposite sides of the first chimeric sequence.
3. The signal activatable construct of claim 1 , wherein the inactive conformation the DNA region of the second chimeric sequence hybridizes with an RNA-DNA region of the second chimeric sequence.
4. The signal activatable construct of claim 1 , wherein the complementary binding of the at least one signal polynucleotide to the signal detection region results in a duplex polynucleotide having approximately 20 consecutive base pairs.
5. The signal-activated polynucleotide construct of claim 1 , wherein the construct comprises one or more 2′-o-methyl modifications that inhibit PKR and/or TLR activation.
6. The signal-activatable polynucleotide construct of claim 1 , wherein the signal activatable construct is in a configuration such that at 37° C. in physiological conditions, a form of the signal activatable construct in absence of the signal polynucleotide is at least about 5 kcal/mole, lower in free energy than a form of said signal activatable construct in presence of the signal polynucleotide.
7. The signal-activatable polynucleotide construct of claim 1 , comprising two or more single-stranded polynucleotides.
8. The signal-activatable polynucleotide construct of claim 7 , wherein nucleotides with chemical modifications, if any, are largely present on one or more said single-stranded polynucleotides.
9. The signal-activatable polynucleotide construct of claim 7 , wherein the signal-activatable polynucleotide is not activated in the presence of the signal polynucleotide when one or more said single-stranded polynucleotides are removed from the construct.
10. The signal-activatable polynucleotide construct of claim 7 , wherein two or more of said single-stranded polynucleotides are covalently linked by a linker moiety (such as PEG) or a bond other than canonical polynucleotide linkage.
11. The signal-activatable polynucleotide construct of claim 1 , configured to have two or more signal polynucleotides bind simultaneously or sequentially to different portions of said signal detection region.
12. The signal-activatable polynucleotide construct of claim 1 , wherein the targeting domain comprises a guide sequence and a sense sequence forming a duplex region of no more than 19 base pairs in length.
13. The signal-activatable polynucleotide construct of claim 12 , wherein the duplex region comprises one or more chemical modifications that confer resistance to nuclease degradation.
14. The signal-activatable polynucleotide construct of claim 12 , wherein in the absence of the signal polynucleotide, the guide sequence and the sense sequence form a double-stranded region comprising one or more chemical modifications that inhibits Dicer cleavage and/or productive RISC incorporation.
15. The signal-activatable polynucleotide construct of claim 12 , wherein the guide sequence is substantially complementary to a transcript of a target gene.
16. The signal-activatable polynucleotide construct of claim 1 , wherein the targeting domain is configured to interfere with a target intracellular process of the cells through RNAi in presence of the signal polynucleotide.
17. The signal-activatable polynucleotide construct of claim 1 , wherein the targeting domain comprises siRNA, microRNA, and/or additional duplex structure is suitable to be used in connection with RNA interfering.
18. The signal-activatable polynucleotide construct of claim 1 , wherein in the absence of the signal polynucleotide, generation of the siRNA or miRNA and/or productive incorporation of said siRNA or miRNA into RISC is inhibited by at least about 2-fold, 5-fold, 10-fold, or 20-fold or more.
19. A method to inhibit expression of a target gene, comprising providing an effective amount of the signal-activated polynucleotide construct of claim 1 and the said signal polynucleotide.
20. The method of claim 19 , wherein said target gene is within a cell.
21. The method of claim 20 , wherein the cell is contacted with the signal-activated polynucleotide construct in vitro.
22. The method of claim 20 , wherein the cell is that of a human, a non-human primate, a non-primate mammal, a rodent, a livestock animal, a bird, an insect, a fly, a worm, or a plant.
23. A pharmaceutical composition comprising an effective amount of one or more of the signal-activated polynucleotide construct of claim 1 and a pharmaceutically acceptable amount of excipients, carriers, or diluents.
24. A vector encoding the signal-activated polynucleotide construct of claim 1 .
25. A cell comprising the signal-activated polynucleotide construct of claim 1 .